Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | KLF5 | Q13887 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | ATP1A1 | P05023 | 2/20 | 1.00 |
| ▸ | ATP1B1 | P05026 | 2/20 | 1.00 |
| ▸ | ATP1A3 | P13637 | 2/20 | 1.00 |
| ▸ | ATP1B2 | P14415 | 2/20 | 1.00 |
| ▸ | ATP1A2 | P50993 | 2/20 | 1.00 |
| ▸ | ATP1B3 | P54709 | 2/20 | 1.00 |
| ▸ | FXYD2 | P54710 | 2/20 | 1.00 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ouabain SCHEMBL14633742 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL17936503 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL2318232 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL10044992 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL24444049 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL18922524 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL24951415 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL21960066 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL21960068 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL22824877 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10301 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102542-A1 | ATPASE INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NON-NEUROLOGICAL DISORDERS | HAPLO THERAPEUTICS INC. (CA) | 2026-05-21 | — | — | WO | claimed |
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIV OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-12516131-B2 | Methods for preventing acute kidney injury | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2026-01-06 | — | — | US | claimed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| US-20250295693-A1 | HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS) | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2025-09-25 | — | — | US | claimed |
| US-20250295668-A1 | METHODS FOR INDUCING COLANIC ACID BIOSYNTHESIS | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2025-09-25 | — | — | US | claimed |
| EP-4615377-A1 | DRUG-CONTAINING DEVICES, SUPRACHOROIDAL SPACE IMPLANTS, AND ADAPTERS FOR INJECTION | Beijing Sightnovo Medical Technology Co., Ltd (CN) | 2025-09-17 | — | — | EP | claimed |
| US-20250221991-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER METASTASES | UNIVERSITY OF CINCINNATI (US) | 2025-07-10 | — | — | US | claimed |
| EP-0108147-A1 | Use of a protoberberine alkaloid and composition containing same. | MAROKO PETER R | 1984-05-16 | — | — | EP | claimed |
| EP-0106370-A2 | Specific binding assays utilizing analyte-cytolysin conjugates | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-04-25 | — | — | EP | claimed |
| EP-0105360-A1 | ANTIBODIES HAVING DUAL SPECIFICITIES, THEIR PREPARATION AND USES THEREFOR | HYBRITECH INCORPORATED (US) | 1984-04-18 | — | — | EP | claimed |
| US-4434236-A | Immunoassay wherein labeled antibody is displaced from immobilized analyte-analogue | E. I. DU PONT DE NEMOURS & CO. (US) | 1984-02-28 | — | — | US | claimed |
| WO-1983003970-A1 | COMPOUNDS, COMPOSITIONS AND METHOD OF TREATMENT FOR IMPROVING CIRCULATORY PERFORMANCE | MAROKO PETER R | 1983-11-24 | — | — | WO | claimed |
| WO-1983003679-A1 | ANTIBODIES HAVING DUAL SPECIFICITIES, THEIR PREPARATION AND USES THEREFOR | HYBRITECH INC (US) | 1983-10-27 | — | — | WO | claimed |
| US-4407945-A | Constitutive production of interleukin 2 by a T cell hybridoma | IMMUNEX CORPORATION (US) | 1983-10-04 | — | — | US | claimed |
| US-4202888-A | IN NONAQUEOUS GLYCERIDE VEHICLE | KALI-CHEMIE PHARMA GMBH. (DE) | 1980-05-13 | — | — | US | claimed |
| US-4105410-A | BLOCKING AGENT FOR RECEPTOR SITES TO PREVENT ADHESION TO SUBSTRATE, DEAGGREGATING AGENT; DISPLACEMENT | BECTON, DICKINSON AND COMPANY (US) | 1978-08-08 | — | — | US | claimed |
| US-4020159-A | Methods of and medications for treating cardiac disorders by using strophanthin | APOTHEKER A. HERBERT K.G., FABRIK PHARMAZEUTISCHER PRAPARATE WIESBADEN (DT) | 1977-04-26 | — | — | US | claimed |